Con­tend­ing for CD47 throne, Arch On­col­o­gy scores $50M as it ramps up PhI stud­ies

Arch On­col­o­gy, one of the old­er star­tups in a crop of im­muno-on­col­o­gy play­ers chas­ing af­ter the CD47 tar­get, has bagged $50 mil­lion to fu­el a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.